在治疗过程中,严重喘的临床缓解与现实世界的长期生物使用
Bradley E Chipps1, Njira Lugogo2, Warner Carr3
1Capital Allergy and Respiratory Disease Center, Sacramento, Calif.
近一半的严重喘患者在长期生物治疗后实现了临床缓解. 这项实践研究表明,临床缓解是严重喘管理的可行目标.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 有限的现实世界数据存在于接受长期生物治疗的严重喘 (SA) 患者的临床缓解率.
- 了解缓解比例对于优化SA管理策略至关重要.
研究的目的:
- 为了确定SA的成人的比例和特征,通过生物治疗实现临床缓解.
- 评估临床缓解作为SA的治疗目标的可行性.
主要方法:
- 在CHRONICLE研究中,观察到美国成年人患有AS,由子专家治疗.
- 数据包括恶化,生物使用,喘控制测试 (ACT) 成绩和专家评估.
- 临床缓解被定义为没有恶化/系统性皮质类固醇,ACT显著改善,并在12个月间隔内控制喘.
主要成果:
- 在611名可评估患者中,平均生物使用时间为39.6个月,46.0%的人在某个时候实现了临床缓解.
- 79.9%的人至少经历了一年没有恶化或系统性皮质类固醇使用.
- 临床缓解的患病率随着生物治疗持续时间的延长而增加.
结论:
- 在现实世界队列中,近一半的SA患者在治疗期间通过延长的生物疗法实现了临床缓解.
- 临床缓解是严重喘患者接受至少一年生物治疗的可实现治疗目标.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
COPD: Management Using Bronchodilators and Corticosteroids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
